←
J Roberts1,076 posts
J Roberts avatar

J Roberts

@JonRob08

Classical hematologist; hemostasis/thrombosis, hemophilia, VWD, rare bleeding disorders specialist; severe hemophilia A blood brother🩸, opinions my own

◷ Joined December 2019▧ 99 Photos and videos
VJHemOnc avatar
⟳ J Roberts retweeted
VJHemOnc@VJHemOnc·Jan 3

In a recent interview, @JonRob08 of @BloodExpertsIL discusses the findings of a study evaluating joint health status & bleeding phenotype in patients with severe & non-severe #hemophilia A or B using musculoskeletal ultrasound and other clinical tools.🩸 Watch here: 👉 ow.ly/YRzs50XLmKr #Hematology #ASH25

J Roberts avatar
J Roberts@JonRob08·28 Oct 2025

Interesting news and was really only a matter of time. Companies should listen to patients, and each individual weigh risks/benefits of all evolving hemophilia therapies. Sometimes patience is the wise approach. #hemophilia #genetherapy reuters.com/business/healthc…

J Roberts avatar
J Roberts@JonRob08·21 May 2025

Happy to share our study of recombinant VWF real-world treatment patterns and outcomes at 11 centers in the U.S. We demonstrate that routine rVWF prophylaxis reduced bleed rate and healthcare resource utilization compared to prior VWD treatments. #VWD #VWF tandfonline.com/doi/full/10.…

J Roberts avatar
J Roberts@JonRob08·26 Feb 2025

Proud to work with esteemed colleagues to improve future research priorities. The patient voice, through lived experience experts, must be incorporated into cutting-edge research programs from start to finish. ashpublications.org/bloodadv…

Mark Skinner avatar
⟳ J Roberts retweeted
Mark Skinner@MSkinnerDC·9 Dec 2024

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and VWD. onlinelibrary.wiley.com/doi/… This article developed by a global team of 48 experts and international organizations rigorously examines a number of GRADE methodology adaptations.

Brian O Mahony avatar
⟳ J Roberts retweeted
Brian O Mahony@Brianhemophilia·6 Dec 2024

A critique of the ISTH Haemophilia Guidelines was published in #Haemophilia Journal today with 49 eminent authors representing a global mixture of expertise, all united in their serious concerns about these guidelines which were already outdated on publication 1/3

Post attachment
Brian O Mahony avatar
⟳ J Roberts retweeted
Brian O Mahony@Brianhemophilia·15 Nov 2024

Centessa have discontinued development of their rebalancing agent, Serpin PC despite encouraging Phase 2 PREScent clinical trial results Decision due to competition from marstacimab and possibly concizumab. This leaves these 2 plus Fitusiran in trials or licenced @ProfMakris

Post attachment